Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myost-D is a branded nutraceutical combination product marketed by Sugen Pharma, an Ahmedabad-based pharmaceutical company. The formulation typically consists of **myo-inositol** and **cholecalciferol (Vitamin D3)**. It is primarily indicated for the management of **Polycystic Ovary Syndrome (PCOS)** and associated **ovulatory dysfunction**. Myo-inositol acts as an insulin-sensitizing agent, serving as a precursor for second messengers that mediate insulin signaling, thereby helping to restore hormonal balance, improve menstrual regularity, and enhance oocyte quality. Vitamin D3 is included to address common deficiencies in women with PCOS, supporting metabolic health and bone density. The product is marketed as a branded generic tablet in India.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Myost-D.